Stability of crossbite correction (relapse of molar expansion) · Children and adults with a posterior crossbite, without a Class III skeletal relationship, cleft lip or palate (or both), or other…
1 finding from 1 review
Molar expansion · Children and adults with a posterior crossbite, without a Class III skeletal relationship, cleft lip or palate (or both), or other…
1 finding from 1 review
Incidence of ORN · Adults with head and neck cancer undergoing curative or adjuvant radiotherapy (at risk of osteoradionecrosis of the jaws)
It is very uncertain whether hyperbaric oxygen therapy (HBO) following extractions changes incidence of ORN compared with perioperative antibiotic prophylaxis (penicillin G) following… (very low certainty).
1 finding from 1 review
Adverse effects · Adults with head and neck cancer undergoing curative or adjuvant radiotherapy (at risk of osteoradionecrosis of the jaws)
1 finding from 1 review
Adverse effects were an outcome of interest in the study conducting this comparison, however no mention was made of the presence or absence of any adverse events
1 study · 74 participants
Very low
Death or dependency at end of · dysphagia in acute and subacute stroke
Swallowing therapy showed no clear difference in death or dependency at end of trial compared with placebo (moderate certainty).
1 finding from 1 review
Case fatality · dysphagia in acute and subacute stroke
Swallowing therapy showed no clear difference in case fatality at end of trial compared with placebo (moderate certainty).
1 finding from 1 review
Length of stay (inpatients only) · dysphagia in acute and subacute stroke
1 finding from 1 review
Dysphagia · dysphagia in acute and subacute stroke
Swallowing therapy may leads to lower proportion of participants with dysphagia at end of trial compared with placebo (low certainty).
1 finding from 1 review
Penetration aspiration score · dysphagia in acute and subacute stroke
1 finding from 1 review
Adverse event: chest infection or pneumonia · dysphagia in acute and subacute stroke
It is very uncertain whether swallowing therapy changes adverse event: chest infection or pneumonia compared with placebo (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in induction of clinical remission CDAI < 150 compared with placebo (low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 70‐point clinical response CDAI compared with placebo (low certainty).
1 finding from 1 review
Induction of 5‐point endoscopic response CDEIS · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 5‐point endoscopic response CDEIS compared with placebo (low certainty).
1 finding from 1 review
Sleep disturbance (adverse event) · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in sleep disturbance (adverse event) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in withdrawals due to adverse outcomes compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality: at 3 years · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
1 finding from 1 review
Proportion of participants without tumour response (CR+PR) · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).
1 finding from 1 review
Serious adverse events · primary hepatocellular carcinoma
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Health‐related quality of life · primary hepatocellular carcinoma
1 finding from 1 review
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review